Who is sponsoring NCT04767204?

NCT04767204 is sponsored by Yu-Li Hospital.

What drugs are being tested in NCT04767204?

Interventions in NCT04767204: peer co-delivered vocational rehabilitation service.

What condition does NCT04767204 study?

NCT04767204 studies Schizophrenia.

Is NCT04767204 still recruiting?

NCT04767204 is currently completed. Last updated 23 February 2021.

Last reviewed 2021-02-23 · How we verify

NCT04767204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Outcomes Among Persons With Schizophrenia Under the Peer-support Service in Vocational Rehabilitation Program

Completed NA Last updated 23 February 2021

What this trial tests

NA trial testing peer co-delivered vocational rehabilitation service in Schizophrenia in 46 participants. Completed in 30 December 2019.

Timeline

1 April 2017

Primary endpoint
28 September 2018

30 December 2019

Quick facts

Lead sponsor	Yu-Li Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	46
Start date	1 April 2017
Primary completion	28 September 2018
Estimated completion	30 December 2019
Sites	1 location across Taiwan

Drugs / interventions tested

peer co-delivered vocational rehabilitation service

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Yu-Li Hospital

Who can join

20 and older, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are few programs related to vocational peer support services in persons with psychiatric disability in Taiwan. This study aims to develop a peer co-lead services in the community rehabilitation center and evaluate the outcomes among service users with schizophrenia under the integrated peer-support services in a supported employment program.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The social support, mental health, psychiatric symptoms, and functioning of persons with schizophrenia participating in peer co-delivered vocational rehabilitation: a pilot study in Taiwan.
Cheng KY, Yen CF. · · 2021 · cited 9× · PMID 34034693 · DOI 10.1186/s12888-021-03277-0

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04767204 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yu-Li Hospital
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04767204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing